Mallinckrodt Sets Out Four Priorities For 2019 And Foresees Specialty Generics Growth
Completing the planned spin-off of its specialty generics and API business into an independent publicly-traded company is one of four priorities that Mallinckrodt has set out for 2019. Despite expecting a “relatively negative” pricing environment this year, chief executive Mark Trudeau believes the Specialty Generics division will achieve growth.
You may also be interested in...
Mallinckrodt has altered the composition of the Specialty Generics business that it plans to spin off by the end of this year, removing its Amitiza brand. The firm says it now has a “full management team in place” for the Specialty Generics unit after naming Eric Slusser as chief financial officer, to serve under president and CEO Matthew Harbaugh.
The latest people movements in the generics and biosimilars industries include Akorn gaining a head of quality, Polpharma naming a chief commercial officer, Pfenex appointing a new chief scientific officer, Coherus announcing a new legal head, Mallinckrodt recruiting a former Impax chief financial officer, and board changes at Krka, Advanz and Hikma.
Under plans announced last December, Mallinckrodt is to spin off its specialty generics and API business; at the recent Annual J.P. Morgan Healthcare Conference, management painted a timeline to completing the project and provided details on the business’ financing and growth prospects.